Shandong Cancer Hospital and Institute clinical trial pipeline

6 trials changed in the last 30 days: 1 stopped, 4 with notable changes, 1 with a minor change only.

1. Stopped

   SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C…SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

   Recruitment suspended

   Shandong Cancer Hospital and Institute·Phase 2· NCT07274774· Registry history of NCT07274774 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Notable

   RAD-NALIRIFOX · Stereotactic Body Radiotherapy and NALIRIFOX…RAD-NALIRIFOX · Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer

   Enrollment reopened

   Shandong Cancer Hospital and Institute·Phase 2· NCT07173387· Registry history of NCT07173387 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Notable

   SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and…SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

   Recruitment opened

   Shandong Cancer Hospital and Institute·Phase 2· NCT07683221· Registry history of NCT07683221 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

4. Notable

   Concordance Between Large Language Model and Multidisciplinary…Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer

   Recruitment opened

   Shandong Cancer Hospital and Institute·Not specified· NCT07595107· Registry history of NCT07595107 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

5. Notable

   Delayed Systemic Therapy Following Destructive Local Treatment of…Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer

   Enrollment increased: 22 → 35 participants

   Shandong Cancer Hospital and Institute·Phase 2· NCT06778382· Registry history of NCT06778382 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.